SK Biopharm Holds Local Sales Meeting in the U.S.

Accelerating Growth in the U.S. Market with Record-Breaking Annual Profit

Lee Dong-hoon, President of SK Biopharm, is giving a presentation at the '2025 National Sales Meeting' held from the 10th to the 13th (local time) in Las Vegas, Nevada, USA, targeting the sales organization within the United States. Photo by SK Biopharm

SK Biopharm's U.S. subsidiary, SK Life Science, announced that it held the '2025 National Sales Meeting' for its U.S. sales organization from the 10th to the 13th (local time) in Las Vegas, Nevada.

Marking its 6th year, approximately 170 local employees, including President Donghoon Lee, attended the event. The attendees celebrated the record-breaking annual profit achieved through the explosive growth of Cenobamate, shared future goals and strategies, and strengthened their unity.

SK Biopharm recorded its first annual profit last year solely from Cenobamate sales. Last year, Cenobamate (U.S. product name XCOPRI®) sales in the U.S. rose 62% year-over-year, reaching an annual revenue of 438.7 billion KRW, laying the foundation to become a global blockbuster new drug. This year, the company plans to expand the patient base and implement aggressive marketing strategies, including the first-ever DTC (Direct-to-consumer) advertising, to enable early prescriptions of Cenobamate even for mild patients.

The National Sales Meeting consisted of ▲motivating the sales organization ▲sharing vision and core strategies ▲workshop sessions for strategy execution. Attendees discussed effective sales strategies through role-playing and practical workshops, focusing on maximizing field execution capabilities. They also shared real experiences from prescribing doctors and patients and conducted Q&A sessions to deeply analyze customer insights.

On the 12th, President Lee delivered a CEO presentation reviewing past sales and prescription volume (TRx) performance and shared the goals and growth strategies for 2025. He emphasized, "The outstanding sales growth achieved last year was all thanks to the dedication and efforts of our employees. SK Biopharm now stands at a critical turning point for future growth based on solid sales. We must now accelerate sales expansion and create sustainable growth through innovation and investment."

Meanwhile, the National Sales Meeting is an event held by U.S. pharmaceutical companies to motivate their sales organizations and share future visions. SK Life Science, SK Biopharm's local subsidiary building a direct sales organization and system in the U.S., is the first Korean pharmaceutical company to hold this event in the United States.

This content was produced with the assistance of AI translation services.